Adam Vandervoort Sells 7,906 Shares of Teladoc Health (NYSE:TDOC) Stock

Teladoc Health, Inc. (NYSE:TDOC) insider Adam Vandervoort sold 7,906 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the sale, the insider owned 110,261 shares in the company, valued at approximately $841,291.43. This represents a 6.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Price Performance

Shares of NYSE TDOC opened at $7.29 on Friday. The business’s 50 day moving average price is $6.17 and its 200 day moving average price is $6.22. The firm has a market cap of $1.32 billion, a P/E ratio of -7.51 and a beta of 2.14. Teladoc Health, Inc. has a 52 week low of $4.40 and a 52 week high of $9.77. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The firm had revenue of $613.85 million during the quarter, compared to analysts’ expectations of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health’s quarterly revenue was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, sell-side analysts expect that Teladoc Health, Inc. will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TDOC. Federated Hermes Inc. grew its stake in shares of Teladoc Health by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock valued at $2,379,000 after purchasing an additional 1,450 shares during the last quarter. Creative Planning grew its stake in shares of Teladoc Health by 7.7% in the 3rd quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock valued at $159,000 after purchasing an additional 1,462 shares during the last quarter. Krane Funds Advisors LLC grew its stake in shares of Teladoc Health by 13.4% in the 3rd quarter. Krane Funds Advisors LLC now owns 12,431 shares of the health services provider’s stock valued at $106,000 after purchasing an additional 1,469 shares during the last quarter. State of Wyoming grew its stake in shares of Teladoc Health by 2.1% in the 3rd quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock valued at $611,000 after purchasing an additional 1,628 shares during the last quarter. Finally, Syon Capital LLC grew its stake in shares of Teladoc Health by 19.1% in the 4th quarter. Syon Capital LLC now owns 14,140 shares of the health services provider’s stock valued at $99,000 after purchasing an additional 2,264 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TDOC shares. Bank of America upgraded Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Thursday, February 26th. Canaccord Genuity Group lowered their price objective on Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Piper Sandler restated an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research report on Thursday, February 26th. Citigroup upped their price objective on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Finally, JPMorgan Chase & Co. lowered their price objective on Teladoc Health from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, March 13th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $7.43.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.